|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
215 897 | 252 318 | 216 827 | 203 159 | 203 159 | - |
| Entreprise Value (EV)1 |
239 396 | 275 225 | 259 147 | 246 690 | 237 167 | 230 444 |
| P/E ratio |
10,3x | 23,3x | 13,7x | 11,8x | 15,1x | 13,4x |
| Yield |
3,53% | 3,12% | 3,68% | 3,98% | 4,23% | 4,44% |
| Capitalization / Revenue |
4,11x | 4,70x | 4,19x | 4,21x | 3,80x | 3,99x |
| EV / Revenue |
4,56x | 5,13x | 5,01x | 5,12x | 4,43x | 4,52x |
| EV / EBITDA |
11,3x | 12,6x | 12,3x | 11,1x | 9,86x | 9,83x |
| Price to Book |
3,04x | 3,94x | 3,43x | 2,87x | 2,53x | 2,40x |
| Nbr of stocks (in thousands) |
5 960 707 | 5 780 475 | 5 534 122 | 5 558 397 | 5 558 397 | - |
| Reference price (USD) |
36,2 | 43,7 | 39,2 | 36,6 | 36,6 | 36,6 |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
52 546 | 53 647 | 51 750 | 48 216 | 53 492 | 50 947 |
| EBITDA1 |
21 172 | 21 814 | 21 097 | 22 208 | 24 047 | 23 432 |
| Operating profit (EBIT)1 |
19 468 | 20 042 | 19 420 | 17 868 | 20 882 | 19 830 |
| Operating Margin |
37,0% | 37,4% | 37,5% | 37,1% | 39,0% | 38,9% |
| Pre-Tax Profit (EBT)1 |
12 305 | 11 885 | 17 682 | 13 166 | 15 574 | 16 971 |
| Net income1 |
21 308 | 11 153 | 16 273 | 19 801 | 14 988 | 13 589 |
| Net margin |
40,6% | 20,8% | 31,4% | 41,1% | 28,0% | 26,7% |
| EPS2 |
3,52 | 1,87 | 2,87 | 3,10 | 2,41 | 2,72 |
| Dividend per Share2 |
1,28 | 1,36 | 1,44 | 1,46 | 1,55 | 1,62 |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 01/22/2021 | 01/15/2021 | 01/22/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
23 499 | 22 907 | 42 320 | 43 531 | 34 008 | 27 285 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
1,11x | 1,05x | 2,01x | 1,96x | 1,41x | 1,16x |
| Free Cash Flow1 |
14 514 | 13 785 | 10 412 | 15 533 | 17 820 | 18 789 |
| ROE (Net Profit / Equities) |
24,6% | 16,6% | 25,7% | 26,4% | 21,7% | 21,9% |
| Shareholders' equity1 |
86 671 | 67 357 | 63 275 | 75 105 | 68 987 | 62 038 |
| ROA (Net Profit / Asset) |
9,37% | 6,73% | 9,96% | 13,7% | 8,44% | 9,55% |
| Assets1 |
227 460 | 165 609 | 163 456 | 144 530 | 177 684 | 142 294 |
| Book Value Per Share2 |
11,9 | 11,1 | 11,4 | 12,7 | 14,4 | 15,2 |
| Cash Flow per Share2 |
2,72 | 2,65 | 2,22 | 1,26 | 2,89 | - |
| Capex1 |
1 956 | 2 042 | 2 176 | 2 041 | 2 115 | 2 049 |
| Capex / Sales |
3,72% | 3,81% | 4,20% | 4,23% | 3,95% | 4,02% |
| Last update |
01/30/2018 | 01/29/2019 | 01/28/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
BioNTech investor, amid worry over shortage, vows vaccines to be delivered for second shot |
Capitalization (USD) 203 159 395 693 Net sales (USD) 51 750 000 000 Number of employees 88 300 Sales / Employee (USD) 586 070 Free-Float capitalization (USD) 120 109 851 403 Avg. Exchange 20 sessions (USD) 1 182 141 155 Average Daily Capital Traded 0,58%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
